YAS Lab members at the 2026 orientation

Department of Pathology · Taipei Medical University

Finding the 2% of a tumor that brings cancer back.

Cancer stem cells make up only 0.1–2% of a tumor, yet they drive therapy resistance, recurrence and metastasis. We isolate them, map what keeps them alive, and build therapies to eliminate them.

01 — Research

Core-to-surface: three ways to target CSCs

Read about cancer stem cells →

Nucleus

Transcription factors

Small-molecule inhibitors against PBX1, a master regulator that keeps cancer stem cells in their resistant state.

Metabolism

Metabolic engines

Targeting glutamine metabolism (GLS) and the metabolic flexibility that lets resistant cells survive treatment.

Surface

Neoantigens & delivery

Cell therapy and acid-responsive nanoparticles that recognize and reach cancer stem cells directly.

Also: induced pluripotent stem cells · regenerative cell therapy · biomarker discovery · radioresistance

02 — Latest publications

Recent work

All 42 publications →

2026.07

Key challenges in communication across milestones of cancer care continuum: a systematic review

Nguyen VC, Tran K, Phan DT, Pham NT, Shen YA, Chen CL, Huang TW. BMC Palliat Care. 2026 Jul 3;25(1):281.

2026.06

Fibronectin 1 mediates pressure-induced aggressive phenotypes in colorectal cancer cells and cancer stem cells

Nguyen VC, Cheng KC, Phan TT, Ho TL, Lin YH, Kuo LJ, Shen YA, Chen CL., Cancer Cell Int., 2026 Jun 12;26(1):289.

2026.06

Critical radiosensitizing parameters of dual-modality gold nanodandelion against cancer radioresistance in MV X-ray and proton therapies

Chuang, Y. C., Chiou, J. F., Wu, P. H., Shen, Y. A., Chang, W. M., Hsia, Y., Kuo, C. C., Wang, W. J., Lo, L. W. & Lee, H. L., Jun 2026, In: Materials Today Advances. 30, 100757.

Yao-An Shen, PhD

03 — Principal investigator

Yao-An Shen, PhD

Associate Professor, Department of Pathology & Graduate Institute of Clinical Medicine, Taipei Medical University

Trained at National Yang-Ming University and Johns Hopkins University, Dr. Shen bridges basic cancer stem cell biology and clinical translation. He holds more than 10 patents, has received nine Young Investigator Awards, and founded Enlighten Biomedicine in 2024.

05 — Collaborators

Working with

  • Taipei Medical University
  • Taipei Medical University Hospital
  • Taipei Municipal Wanfang Hospital
  • Taipei Medical University – Shuang Ho Hospital
  • Johns Hopkins University
  • Academia Sinica
  • National Yang Ming Chiao Tung University
  • National Taiwan University
  • National Science and Technology Council
  • Case Western Reserve University

Join us

Help shape the future of cancer stem cell research.

Postdocs, PhD and master's students, research assistants and interns.

See opportunities